Search

Don X Zhang

from Princeton, NJ
Age ~67
Get Report
Also known as:
Don K Zhang, Xiaodong Dong Zhang, Don D Zhang, Xiaodong D Zhang, Xiao Dong Zhang, Xiao Q Zhang
Related to:
Yiqing Q Chen, 71
Connected to:
Aaron N Zhang, 60Adelaide X Zhang, 48Aiai Zhang, 38Aijun Zhang, 70Airong Zhang, 72Alfred Zhang, 31Anderson Zhang, 34Angeline Zhang, 36Anli Zhang, 68Anming Zhang, 64

Don Zhang Phones & Addresses

  • Princeton, NJ
  • Plainsboro, NJ
  • Branford, CT
  • New Haven, CT
  • Portage, MI
  • Old Lyme, CT
  • Staten Island, NY

Work

Company: Beta pharma, inc Address: 25 Science Park, New Haven, CT 06510 Phones: (203) 786-5436 Position: President Industries: Functions Related to Depository Banking

Resumes

Resumes

Don Zhang Photo 1

Don Zhang

View page
Location:
6415 Palomino Park, Kalamazoo, MI 49009
Industry:
Biotechnology
Work:
Beta Pharma, Inc. May 1996 - Jun 2003
Executive Director of Drug Discovery
Education:
University of Maryland 1990 - 1996
Doctorates, Doctor of Philosophy, Philosophy, Organic Chemistry University of Massachusetts Boston 1986 - 1990
Masters, Organic Chemistry Lanzhou University 1978 - 1982
Bachelors, Bachelor of Science, Chemistry Lanzhou University 1978 - 1982
Doctorates, Doctor of Philosophy, Philosophy, Chemistry, Organic Chemistry
Skills:
Drug Discovery
Organic Chemistry
Pharmaceutical Industry
Biotechnology
Organic Synthesis
Lifesciences
Technology Transfer
Regulatory Affairs
Don Zhang Photo 2

Don Zhang

View page
Don Zhang Photo 3

Don Zhang

View page
Don Zhang Photo 4

Don Zhang

View page
Don Zhang Photo 5

Student At University Of Nebraska-Lincoln

View page
Location:
United States
Industry:
Semiconductors

Business Records

Name / Title
Company / Classification
Phones & Addresses
Don Zhang
President
Beta Pharma, Inc
Functions Related to Depository Banking
25 Science Park, New Haven, CT 06510
Don Zhang
Owner
Beta Pharma Inc
Nonclassifiable Establishments
5 Science Park, New Haven, CT 06511
Website: betapharma.com
Don Zhang
Owner
Beta Pharma Inc
5 Science Park, New Haven, CT 06511
(203) 786-5436, (203) 786-5437
Don Zhang
President
Beta Pharma, Inc
Functions Related to Depository Banking
25 Science Park, New Haven, CT 06510
Don Zhang
Owner
Beta Pharma Inc
Nonclassifiable Establishments
5 Science Park, New Haven, CT 06511
Website: betapharma.com

Publications

Us Patents

Novel Fused Quinazoline Derivatives Useful As Tyrosine Kinase Inhibitors

View page
US Patent:
20040048883, Mar 11, 2004
Filed:
Mar 26, 2003
Appl. No.:
10/397660
Inventors:
Don Zhang - Old Lyme CT, US
Guojian Xie - Cheshire CT, US
Charles Davis - Meriden CT, US
Zhenzhuang Cheng - New Haven CT, US
Hang Chen - Waterbury CT, US
Yinxiang Wang - Cheshire CT, US
Mehrnaz Kamal - Shelton CT, US
International Classification:
A61K031/519
C07D239/70
US Classification:
514/267000, 544/249000
Abstract:
The present invention is directed to a compound having the structure wherein A is a 7-18 membered ring that comprises 0 to 6 heteroatoms selected from O, S, and N; Ris selected from the group consisting of hydrogen, halogen, substituted or unsubstituted Calkyl, substituted or unsubstituted Calkenyl, substituted or unsubstituted Calkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclyl; m is an integer from 0 to 3; X is selected from the group consisting of NR, CHR, O, or S; wherein Rand Rare each individually H or Calkyl; R is selected from the group consisting of unsubstituted aryl, and substituted or unsubstituted heteroaryl, substituted or unsubstituted aryl-(C)alkyl, substituted or unsubstituted aryl-(C)cycloalkyl, substituted or unsubstituted heteroaryl-(C)alkyl, and substituted or unsubstituted heteroaryl-(C)cycloalkyl; and pharmaceutically acceptable salts thereof; with the proviso that if A is a 7 or 8 membered ring, then Ris selected from the group consisting of other than H, C-Calkyl, (C-Calkoxy)C-Calkyl, C-Calkanoyl, C-Calkoxy or —S(O)(C-Calkyl) wherein x is 0 to 2, and wherein said alkyl group and the alkyl moieties of said Rgroups are optionally substituted by 1 to 3 halogens. The present invention is also directed to pharmaceutical compositions comprising the above compound, and methods of treating patients suffering from tyrosine kinase-mediated disorders using the above compound.

Anti-Inflammatory And Anti-Thrombotic Compounds And Their Compositions

View page
US Patent:
20050148554, Jul 7, 2005
Filed:
Nov 12, 2004
Appl. No.:
10/986974
Inventors:
Don Zhang - Old Lyme CT, US
Guojian Xie - Cheshire CT, US
Zhengwei Huan - Cheshire CT, US
Hang Chen - Waterbury CT, US
Charles Davis - Meriden CT, US
International Classification:
A61K031/60
C07C023/02
US Classification:
514159000, 558482000
Abstract:
The invention encompasses novel compounds of Formula I, which are anti-inflammatory and anti-thrombotic agents. The invention also encompasses certain pharmaceutical compositions and methods for treatment of cyclooxygenases (COX-1 and COX-2) mediated diseases comprising the use of compounds of Formula I. The above compounds may be used as a combination therapy with low-dose aspirin, NSAIDs, or selective COX-2 inhibitors to treat chronic cyclooxygenases mediated diseases or conditions while simultaneously reducing the risk of thrombotic cardiovascular events.

Icotinib Hydrochloride, Synthesis, Crystalline Forms, Pharmaceutical Compositions, And Uses Thereof

View page
US Patent:
20110182882, Jul 28, 2011
Filed:
Jul 7, 2009
Appl. No.:
13/003216
Inventors:
Yinxiang Wang - Cheshire CT, US
Guojian Xie - Cheshire CT, US
Lieming Ding - Hangzhou, CN
Fenlai Tan - Troy MI, US
Yunyan Hu - Beijing, CN
Wei He - Beijing, CN
Bin Han - Beijing, CN
Wei Long - Beijing, CN
Yong Liu - Beijing, CN
Haima Ai - Beijing, CN
Charles Davis - Germantown WI, US
Don Zhang - Branford CT, US
Assignee:
Beta Pharma, Inc. - Branford CT
International Classification:
A61K 39/395
C07D 491/056
A61K 31/519
A61K 38/43
A61P 35/00
US Classification:
4241301, 544250, 514267, 424 941
Abstract:
The invention relates to 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, its therapeutic usage for treatment of diseases mediated by EGFR kinase and its combinatory therapeutic usage together with other therapeutic agents. The invention also provides synthetic methods for preparation of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, and the relevant synthetic intermediates for synthesis of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride.

New Indolinone Protein Kinase Inhibitors

View page
US Patent:
20120258995, Oct 11, 2012
Filed:
Apr 6, 2012
Appl. No.:
13/441813
Inventors:
Don Zhang - Branford CT, US
Guojian Xie - Cheshire CT, US
Assignee:
Beta Pharma, Inc - Branford CT
International Classification:
A61K 31/404
A61P 35/00
C07D 413/14
US Classification:
514414, 540467
Abstract:
The present invention relates to new indolinone compounds and their pharmaceutically acceptable salts and prodrugs for treating and preventing VEGFR related cellular disorders such as cancer.

Treatment Of Egfr Mutant-Related Cancers Using A Combination Of Egfr And Cdk4/6 Inhibitors

View page
US Patent:
20220347177, Nov 3, 2022
Filed:
Sep 23, 2020
Appl. No.:
17/641868
Inventors:
- Wilmington DE, US
Michael John Costanzo - Bonney Lake WA, US
Michael Alan Green - Easton PA, US
Don Zhang - Princeton NJ, US
Jirong Peng - Mequon WI, US
International Classification:
A61K 31/506
A61P 35/00
A61P 11/00
Abstract:
Methods of treating EGFR mutant-related cancers with a combination of an EGFR inhibitor of Formula (I) and the CDK4/6 inhibitor of Formula (II) and use of combinations of these compounds in the manufacture of medicaments for the treatment of EGFR mutant-related cancers are disclosed:

2H-Indazole Derivatives As Cdk4 And Cdk6 Inhibitors And Therapeutic Uses Thereof

View page
US Patent:
20210139459, May 13, 2021
Filed:
Jan 29, 2019
Appl. No.:
16/965376
Inventors:
- Wilmington DE, US
Michael John Costanzo - Warminster PA, US
Jirong Peng - Mequon WI, US
Don Zhang - Princeton NJ, US
International Classification:
C07D 401/14
A61K 45/06
Abstract:
2-Aminopyrimidine-substituted 2H-indazole compounds of formula (I), where Ris hydrogen, and their prodrugs, where Ris a metabolizable group under physiological conditions, as cyclin-dependent kinase (CDK) and cell-proliferation inhibitors, and therapeutic uses and methods of preparation thereof, are disclosed. These compounds, and pharmaceutically acceptable salts, solvates, prodrugs, and pharmaceutical compositions thereof, are useful for treating diseases and disorders associated with activity of cyclin-dependent kinases, in particular CDK4/6, including but not limited to various cancers and inflammation-related diseases or conditions.

Substituted 2-Anilinopyrimidine Derivatives As Egfr Modulators

View page
US Patent:
20200216421, Jul 9, 2020
Filed:
Mar 16, 2020
Appl. No.:
16/819539
Inventors:
- Wilmington DE, US
- Shanghai, CN
Michael Nicholas Greco - Lansdale PA, US
Michael Alan Green - Easton PA, US
Victoria Lynn Wilde - Montclair NJ, US
Don Zhang - Princeton NJ, US
Assignee:
Beta Pharma, Inc. - Wilmington DE
Beta Pharma (Shanghai) Co., Ltd. - Shanghai
International Classification:
C07D 403/04
A61K 45/06
C07D 471/04
C07D 403/14
C07D 401/14
A61K 31/506
Abstract:
This application discloses novel substituted 2-anilinopyrimidine derivatives, and pharmaceutically acceptable salts, solvates, prodrugs, and compositions thereof, which are useful for the treatment or prevention of diseases or medical conditions mediated by epidermal growth factor receptors (EGFRs), including but not limited to a variety of cancers.

2-Anilinopyrimidine Derivatives As Therapeutic Agents For Treatment Of Brain Cancers

View page
US Patent:
20190365755, Dec 5, 2019
Filed:
May 11, 2017
Appl. No.:
16/300949
Inventors:
- Wilmington DE, US
Michael John Costanzo - Warminster PA, US
Michael Alan Green - Easton PA, US
Jirong Peng - Mequon WI, US
Victoria Lynn Wilde - Montclair NJ, US
Don Zhang - Princeton NJ, US
Assignee:
Beta Pharma, Inc. - Wilmington DE
International Classification:
A61K 31/506
A61P 35/04
Abstract:
Methods of using substituted 2-anilinopyrimidine derivatives, and pharmaceutically acceptable salts, solvates, or compositions, for the treatment of brain cancers, in particular EGFR-mediated metastatic brain cancer, are disclosed.
Control profile
Don X Zhang from Princeton, NJ, age ~67 Get Report